Kadmos Capital is a UK-based venture capital fund focused on early-stage deep-tech companies with positive impact across artificial intelligence, sustainability and longevity.
Remy serves as Managing Partner at Kadmos Capital. He previously held investment and advisory roles at Deep Science Ventures, Calibrate Management, and Morgan Stanley.
Ada Ventures leads the seed round to support the development of AI voice agents for general practices.
"For most patients, the GP reception desk is the front door to the entire NHS, and it’s under more strain than any other part of the system. InTouchNow was built to handle the repetitive, time-consuming calls so reception teams can focus on the patients who really need a person. Ada’s backing is a strong vote of confidence in British healthtech, and lets InTouchNow bring safe, ethical, and genuinely useful AI to many more NHS practices across the UK."
The pre-seed round was co-led by Kadmos Capital and Exceptional Ventures and will support the transition of designed drug combinations into wet-lab validation.
"Cancer is not one disease driven by one target, but we still develop drugs as if it were. Combinations are how we beat it – and with more than 900 billion of them possible, no lab on earth can test its way to the right ones. That is the problem we built Big Picture Bio to solve: model the disease as the dynamic system it actually is, then design against it – combinations chosen because they are most likely to work in patients, not because they were the ones we could get to. This funding takes our first designed combinations out of the model and into the lab."
The financing round was led by Soulmates Ventures with backing from several new and existing investors.
"Antiverse is tackling one of the most technically demanding problems in drug discovery. The team’s ability to reduce the development time for de novo therapeutic-grade antibodies in a defined domain to under four months is a significant scientific and operational achievement. This capability, combined with the AI-driven design and in-house labs, positions Antiverse on track to become a global leader and the go-to developer of antibody therapies for the most elusive disease targets in medicine"
The oversubscribed financing was led by Ahren Innovation Capital and will support preclinical validation and platform development.
"Partnering with the team at o2h discovery is a fantastic milestone for OutSee as we look ahead to commencing our first drug discovery programme and showcasing the potential of our Nomaly platform to revolutionise target discovery. The agreement is testament to the strength of our technology and, in combination with the closure of our oversubscribed seed funding round, kicks off a very exciting year. Thank you to our investors and supporters for their continued support, and the hard work and dedication of our team."
The funding round will support the development of hospital-ready diagnostic products and broaden clinical access to glycan testing.
"Together with genetics, the concept of personalised medicine requires a dynamic approach. Genomics provides the blueprint of where we begin, but health is not static—it evolves with time, environment, and lifestyle. To truly transform care, we must complement genomic insights with modifiable biomarkers: biological signals that capture real-time responses to interventions and track improvement longitudinally. This synergy between genomics and adaptive biomarkers is the cornerstone for turning personalised medicine from a descriptive concept into actionable, measurable, and preventative healthcare."
.png)
